Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, 1411713116, Tehran, Iran.
Cell Oncol (Dordr). 2012 Oct;35(5):317-34. doi: 10.1007/s13402-012-0095-3. Epub 2012 Sep 7.
MicroRNAs (miRNAs) are a class of non-coding, endogenous, small RNAs that negatively regulate gene expression by inducing degradation or translational inhibition of target mRNAs. Aberrant expression of miRNAs appears to be a common characteristic of hematological malignancies including leukemias.
Here we review the available data supporting a role of aberrant expression of miRNAs in the pathogenesis of leukemias including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).
The expression signatures of miRNAs provide exciting opportunities in the diagnosis, prognosis, and therapy of leukemia. Since miRNAs can function as either oncogenes or tumor suppressor genes in leukemogenesis, the potential of using these small RNAs as therapeutic targets opens up new opportunities for leukemia therapy by either inhibiting or augmenting their activity.
MicroRNAs(miRNAs)是一类非编码、内源性的小 RNA,通过诱导靶 mRNAs 的降解或翻译抑制来负调控基因表达。miRNAs 的异常表达似乎是包括白血病在内的血液恶性肿瘤的共同特征。
本文综述了支持 miRNAs 异常表达在白血病发病机制中的作用的现有数据,包括急性髓系白血病(AML)、急性淋巴细胞白血病(ALL)、慢性髓系白血病(CML)和慢性淋巴细胞白血病(CLL)。
miRNAs 的表达特征为白血病的诊断、预后和治疗提供了令人兴奋的机会。由于 miRNAs 在白血病发生中可以作为癌基因或肿瘤抑制基因发挥作用,因此利用这些小 RNA 作为治疗靶点的潜力通过抑制或增强其活性为白血病治疗开辟了新的机会。